NEW YORK ( TheStreet) -- CHANGE IN RATINGS Apple ( AAPL) rated new buy at Cantor. $777 price target. Stock has been challenged this year, but appears to be in the midst of a recovery. Asbury Automotive ( ABG) upgraded at Keybanc from hold to buy. $60 price target. Estimates also boosted, given higher industry demand. Allison Transmission ( ALSN) upgraded at Goldman to buy. $27 price target. End-market demand is improving and the company gives back its free cash flow in dividends. Best Buy ( BBY) upgraded at BofA/Merrill from underperform to neutral. $38 price target. Company is cutting costs faster than expected. Beam ( VZ) downgraded at Argus from buy to hold, Argus said. Stock is trading at a premium to its peers. CG) downgraded at UBS to neutral from buy and given a $5.69 price target, said UBS. Higher political risk will make the recent run in the stock difficult to continue. CNA Financial ( CNA) rated new buy at Deutsche. $42 price target. Company trades at a deep discount to its peers, but management can expand margins. Concur Technologies ( CNQR) downgraded at Wunderlich from buy to hold. $96 price target. 2014 consensus earnings expectations appear too high. Gulfport Energy ( GPOR) rated new Outperform at Wells. Company's core asset appears to be in a sweet spot of the Utica shale. Guidewire Software ( GWRE) downgraded at Citi to sell from neutral and given a $37 price target, said Citigroup. Revenue growth is decelerating and expenses are ramping, making valuation difficult. Invensense ( INVN) upgraded at Baird from neutral to outperform, Robert Baird said. $23 price target. Design win momentum has swung back to the company's favor. Loews ( L) rated new Buy at Deutsche. $52 price target. Company is the cheapest of its peers, but can compound book value. Microsoft ( MSFT) was downgraded at Morgan Stanley to equal-weight, Morgan Stanley said. Nokia deal adds risk to the company's model. Nokia ( NOK) upgraded at BMO from underperform to market perform, BMO Capital said. $5 price target. MSFT deal terms are very positive for the company.
ServiceNow ( NOW) rated new outperform at JMP Securities. $56 price target. Company is a cloud leader in IT Service Management. Pharmacyclics ( PCYC) upgraded at Lazard to buy, Lazard Capital Markets said. $141 price target. Checks show a strong outlook for ibrutinib. Rowan ( RDC) upgraded at JP Morgan from neutral to overweight, JP Morgan said. Dayrates have likely bottomed. $39 price target. Select Medical ( SEM) downgraded at Wells from market perform to underperform, Wells Fargo said. Long-term acute care hospitals will face Medicare reimbursement risks in 2015. Vivus ( VVUS) downgraded at Lazard to sell, Lazard Capital Markets said. $8 price target. Qsymia has had a slow launch and the company's patents could face competition. Verizon ( VZ) upgraded at Baird from neutral to outperform, Robert Baird said. $53 price target. VZW purchase should benefit long-term positioning and earnings growth.
READ: HP's Still a Value Trap